Join us for a 1-hour webinar

Minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures.

In this webinar you will learn how to perform differential diagnosis of acute leukemia, evaluate ALL MRD and immunodeficiency, and how to design and validate new panels.

Elaine Sobral da Costa, MD, currently head of the flow cytometry department at IPPMG-UFRJ develops her work on the research of new analysis methods for the diagnosis and follow-up of neoplastic diseases. Elaine is a member of the EuroFlow™ consortium and collaborates frequently with Prof. Alberto Orfao’s group in the University of Salamanca. She is currently Associate Professor at the Pediatric department of the UFRJ and permanent teacher of the Clinical Medicine Programme of the UFRJ.

7 PM GMT+2 (Madrid, Spain)
7 PM GMT+2 (Amsterdam, Netherlands)
1 AM GMT+8 (Beijing, China)
3 AM GMT+10 (Sydney, Australia)
2 PM GMT-3 (Rio de Janeiro, Brasil)
1 PM GMT-4 (New York, NY, USA)
10 AM GMT-7 (Los Angeles, CA, USA)
5 PM GMT (London, United Kingdom)